← Back to Screener
Indivior Pharmaceuticals, Inc. Common Stock (INDV)
Price$32.42
Favorite Metrics
Price vs S&P 500 (26W)28.76%
Price vs S&P 500 (4W)2.11%
Market Capitalization$3.99B
P/E Ratio (Annual)1328.95x
All Metrics
P/CF (Annual)110.75x
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)14.91x
Revenue Growth (3Y)14.52%
Cash Flow / Share (Quarterly)$0.96
Price vs S&P 500 (YTD)-13.00%
Gross Margin (TTM)85.51%
Net Profit Margin (TTM)10.59%
EPS (TTM)$0.98
10-Day Avg Trading Volume1.44M
EPS Excl Extra (TTM)$0.98
Revenue Growth (5Y)8.64%
EPS (Annual)$0.02
ROI (Annual)-13.72%
Gross Margin (Annual)85.27%
Net Profit Margin (5Y Avg)-2.70%
Cash / Share (Quarterly)$3.56
P/E Basic Excl Extra (TTM)31.89x
Revenue Growth QoQ (YoY)2.28%
EPS Growth (5Y)-52.00%
P/E Normalized (Annual)1328.95x
ROA (Last FY)0.23%
Revenue Growth TTM (YoY)-0.25%
EBITD / Share (TTM)$1.93
ROE (5Y Avg)62.61%
Operating Margin (TTM)18.73%
Cash Flow / Share (Annual)$0.04
P/B Ratio398.69x
P/B Ratio (Quarterly)230.24x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.27x
Net Interest Coverage (TTM)2.56x
ROA (TTM)8.99%
EPS Growth QoQ (YoY)96.86%
EV / EBITDA (TTM)15.71x
EPS Incl Extra (Annual)$0.02
Current Ratio (Annual)0.89x
Quick Ratio (Quarterly)0.76x
3-Month Avg Trading Volume2.63M
52-Week Price Return260.93%
EV / Free Cash Flow (Annual)772.77x
P/E Incl Extra (TTM)31.89x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.16
P/S Ratio (Annual)3.36x
Asset Turnover (Annual)0.90x
52-Week High$38.00
Operating Margin (5Y Avg)-3.99%
EPS Excl Extra (Annual)$0.02
CapEx CAGR (5Y)34.66%
26-Week Price Return37.51%
Quick Ratio (Annual)0.65x
13-Week Price Return-2.77%
Total Debt / Equity (Annual)5.43x
Current Ratio (Quarterly)0.96x
Enterprise Value$3,863.851
Revenue / Share Growth (5Y)11.44%
Asset Turnover (TTM)0.85x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.12x
Pretax Margin (Annual)1.18%
Cash / Share (Annual)$2.56
3-Month Return Std Dev38.58%
Gross Margin (5Y Avg)84.85%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-33.17%
EBITDA Interim CAGR (5Y)16.98%
ROE (Last FY)-88.24%
Net Interest Coverage (Annual)7.33x
EPS Basic Excl Extra (Annual)$0.02
P/FCF (TTM)19.08x
Receivables Turnover (TTM)4.63x
EV / Free Cash Flow (TTM)32.20x
Total Debt / Equity (Quarterly)27.90x
EPS Incl Extra (TTM)$0.98
Receivables Turnover (Annual)4.68x
ROI (TTM)29.40%
P/S Ratio (TTM)3.38x
Pretax Margin (5Y Avg)-5.01%
Revenue / Share (Annual)$8.93
Tangible BV / Share (Annual)$0.86
Forward P/E10.39x
Free OCF CAGR (5Y)-48.94%
Price vs S&P 500 (52W)225.83%
P/E Ratio (TTM)31.89x
Year-to-Date Return-8.86%
5-Day Price Return3.48%
EPS Normalized (Annual)$0.02
ROA (5Y Avg)-1.62%
Net Profit Margin (Annual)0.25%
Month-to-Date Return7.28%
EBITD / Share (Annual)$0.20
EPS Growth (3Y)-74.29%
Operating Margin (Annual)2.69%
LT Debt / Equity (Annual)4.65x
P/CF (TTM)22.15x
ROI (5Y Avg)20.83%
P/E Excl Extra (TTM)31.89x
LT Debt / Equity (Quarterly)23.50x
EPS Basic Excl Extra (TTM)$0.98
P/TBV (Quarterly)12.23x
P/B Ratio (Annual)49.56x
Inventory Turnover (TTM)1.03x
Pretax Margin (TTM)16.10%
Book Value / Share (Annual)$0.37
Price vs S&P 500 (13W)-5.63%
Net Margin Growth (5Y)-57.03%
Beta4.29x
P/FCF (Annual)797.37x
Revenue / Share (TTM)$9.15
ROE (TTM)159.06%
52-Week Low$8.69
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INDVIndivior Pharmaceuticals, Inc. Common Stock | 3.38x | -0.25% | 85.51% | -52.00% | $32.42 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Indivior Pharmaceuticals specializes in treating opioid use disorder (OUD) through buprenorphine-based pharmaceutical products. Its primary revenue sources are Sublocade, an extended-release monthly injection, and Suboxone, a sublingual film combining buprenorphine and naloxone. The company addresses a significant therapeutic need in the management of opioid dependence as a chronic, treatable medical condition.